CSL Behring ( CSL Behring)

Primary tabs

CSL Behring's picture

Management

Contact Address

About CSL Behring

CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself. Our commitment to saving lives and improving the quality of life for people with serious and rare conditions is evident in everything we do. Whether we are manufacturing and marketing safe and effective products or researching and developing innovative biotherapies, we are first and foremost focused on fulfilling our customers’ needs.

CSL Behring press release, blog etc

Fri, 12/16/2022 - 03:21 CSL Receives Positive CHMP Opinion for Etranacogene Dezaparvovec Gene Therapy for Adults with Hemophilia B
Mon, 12/12/2022 - 17:59 CSL Announces Next CEO & Managing Director
Wed, 11/02/2022 - 16:07 Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022
Tue, 10/25/2022 - 23:43 CSL enters into Strategic Option and License Agreement with Translational Sciences
Tue, 09/13/2022 - 16:50 CSL presents new research and development center in Marburg, Germany
Thu, 09/08/2022 - 17:10 Orphan Drug Designation granted for etranacogene dezaparvovec, CSLs gene therapy for haemophilia B, by the Therapeutics Goods Administration
Tue, 05/24/2022 - 08:44 FDA Accepts CSL Behrings Biologics License Application for Etranacogene Dezaparvovec for Priority Review
Thu, 04/28/2022 - 11:32 CSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding Disorders
Mon, 03/28/2022 - 06:09 European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
Wed, 03/02/2022 - 11:05 Forbes Magazine Ranks Global Biotech Leader CSL Among Americas Best Employers for 2022
Tue, 12/14/2021 - 21:06 CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B
Mon, 10/18/2021 - 00:03 Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and New Strategic Collaborations Among the Highlights from CSL R&D Day
Tue, 10/05/2021 - 05:57 CSL Launches Annual Scholarship Program with Seven Greater Chicago Area Students Receiving Awards
Wed, 09/08/2021 - 21:03 Urban League of Philadelphia Names CSLs Elizabeth Walker to Board of Directors
Tue, 06/08/2021 - 11:01 Hizentra will be covered under the same Medicare benefit category as intravenous immune globulin (IVIg), but with the convenience of self-infusing at home
Sun, 05/16/2021 - 10:47 New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days
Thu, 04/01/2021 - 20:46 CoVIg-19 Plasma Alliance Announces Results from Investigational COVID-19 Hyperimmune Globulin Medicine
Mon, 11/16/2020 - 14:54 Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development
more

InfoBox

HomePagewww.cslbehring.com
Facebookwww.facebook.com/CSL-Behring-51976781570
Twittertwitter.com/CSLBehring
YouTubewww.youtube.com/CSLBehringGlobal
Google+plus.google.com/u/0/+CSLBehringUS
LinkedInwww.linkedin.com/company/csl-behring
Wikipediaen.wikipedia.org/wiki/CSL_Behring